Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[This assumption has been derived by the successful development of BCR/ABL tyrosine kinase inhibitors in human chronic myeloid leukemia as well as on the activity of antiCD20 monoclonal antibodies in lymphoproliferative disease and of anti HER2 agents in breast tumors overexpressing the targeted antigens.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• assertion description "[This assumption has been derived by the successful development of BCR/ABL tyrosine kinase inhibitors in human chronic myeloid leukemia as well as on the activity of antiCD20 monoclonal antibodies in lymphoproliferative disease and of anti HER2 agents in breast tumors overexpressing the targeted antigens.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[This assumption has been derived by the successful development of BCR/ABL tyrosine kinase inhibitors in human chronic myeloid leukemia as well as on the activity of antiCD20 monoclonal antibodies in lymphoproliferative disease and of anti HER2 agents in breast tumors overexpressing the targeted antigens.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[This assumption has been derived by the successful development of BCR/ABL tyrosine kinase inhibitors in human chronic myeloid leukemia as well as on the activity of antiCD20 monoclonal antibodies in lymphoproliferative disease and of anti HER2 agents in breast tumors overexpressing the targeted antigens.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP866289.RAe2ZpQ1nxhHOE_ybDmNy-_Rey-ztEW-Sq_6eUPXapttU130_assertion description "[This assumption has been derived by the successful development of BCR/ABL tyrosine kinase inhibitors in human chronic myeloid leukemia as well as on the activity of antiCD20 monoclonal antibodies in lymphoproliferative disease and of anti HER2 agents in breast tumors overexpressing the targeted antigens.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP866289.RAe2ZpQ1nxhHOE_ybDmNy-_Rey-ztEW-Sq_6eUPXapttU130_provenance.
• NP518930.RAbPK-033PamiZiIbN88XaceyRVKyKl-pQTkfwmmdkSNE130_assertion description "[This assumption has been derived by the successful development of BCR/ABL tyrosine kinase inhibitors in human chronic myeloid leukemia as well as on the activity of antiCD20 monoclonal antibodies in lymphoproliferative disease and of anti HER2 agents in breast tumors overexpressing the targeted antigens.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP518930.RAbPK-033PamiZiIbN88XaceyRVKyKl-pQTkfwmmdkSNE130_provenance.
• NP379013.RAAHbt2UHcwNEVzN2NAItKRuZtTwCYpQHWRmQ2vMYswRs130_assertion description "[This assumption has been derived by the successful development of BCR/ABL tyrosine kinase inhibitors in human chronic myeloid leukemia as well as on the activity of antiCD20 monoclonal antibodies in lymphoproliferative disease and of anti HER2 agents in breast tumors overexpressing the targeted antigens.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP379013.RAAHbt2UHcwNEVzN2NAItKRuZtTwCYpQHWRmQ2vMYswRs130_provenance.
• NP219595.RADr9l1wZK9vl7GGRN-zKSbz4kqDjLCoVssOgcAuANRzI130_assertion description "[This assumption has been derived by the successful development of BCR/ABL tyrosine kinase inhibitors in human chronic myeloid leukemia as well as on the activity of antiCD20 monoclonal antibodies in lymphoproliferative disease and of anti HER2 agents in breast tumors overexpressing the targeted antigens.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP219595.RADr9l1wZK9vl7GGRN-zKSbz4kqDjLCoVssOgcAuANRzI130_provenance.
• NP604553.RA3b7E31ECINa7gePKGbvgXbItCB9W-pyfBzhAq-DzsKY130_assertion description "[This assumption has been derived by the successful development of BCR/ABL tyrosine kinase inhibitors in human chronic myeloid leukemia as well as on the activity of antiCD20 monoclonal antibodies in lymphoproliferative disease and of anti HER2 agents in breast tumors overexpressing the targeted antigens.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP604553.RA3b7E31ECINa7gePKGbvgXbItCB9W-pyfBzhAq-DzsKY130_provenance.
• NP570125.RAK-mXa3ZN07QOpBcsgFKLyKrhI8jRGewbVIWyNEAHBOg130_assertion description "[This assumption has been derived by the successful development of BCR/ABL tyrosine kinase inhibitors in human chronic myeloid leukemia as well as on the activity of antiCD20 monoclonal antibodies in lymphoproliferative disease and of anti HER2 agents in breast tumors overexpressing the targeted antigens.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP570125.RAK-mXa3ZN07QOpBcsgFKLyKrhI8jRGewbVIWyNEAHBOg130_provenance.
• NP219229.RA34jQavo_aOZvJvQI7fQsTTLliamL-oibl2_FZ9G_i4s130_assertion description "[This assumption has been derived by the successful development of BCR/ABL tyrosine kinase inhibitors in human chronic myeloid leukemia as well as on the activity of antiCD20 monoclonal antibodies in lymphoproliferative disease and of anti HER2 agents in breast tumors overexpressing the targeted antigens.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP219229.RA34jQavo_aOZvJvQI7fQsTTLliamL-oibl2_FZ9G_i4s130_provenance.
• assertion description "[This assumption has been derived by the successful development of BCR/ABL tyrosine kinase inhibitors in human chronic myeloid leukemia as well as on the activity of antiCD20 monoclonal antibodies in lymphoproliferative disease and of anti HER2 agents in breast tumors overexpressing the targeted antigens.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[This assumption has been derived by the successful development of BCR/ABL tyrosine kinase inhibitors in human chronic myeloid leukemia as well as on the activity of antiCD20 monoclonal antibodies in lymphoproliferative disease and of anti HER2 agents in breast tumors overexpressing the targeted antigens.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[This assumption has been derived by the successful development of BCR/ABL tyrosine kinase inhibitors in human chronic myeloid leukemia as well as on the activity of antiCD20 monoclonal antibodies in lymphoproliferative disease and of anti HER2 agents in breast tumors overexpressing the targeted antigens.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP491841.RA_huBMH39893zeLquiBfW-6pM4FZ7vzj5FNFxdxDJirU130_assertion description "[This assumption has been derived by the successful development of BCR/ABL tyrosine kinase inhibitors in human chronic myeloid leukemia as well as on the activity of antiCD20 monoclonal antibodies in lymphoproliferative disease and of anti HER2 agents in breast tumors overexpressing the targeted antigens.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP491841.RA_huBMH39893zeLquiBfW-6pM4FZ7vzj5FNFxdxDJirU130_provenance.
• NP491842.RAdAh8GIypCWaMVDqd9YuP8E2IHTGpgo6NLvfYwRw7kc0130_assertion description "[This assumption has been derived by the successful development of BCR/ABL tyrosine kinase inhibitors in human chronic myeloid leukemia as well as on the activity of antiCD20 monoclonal antibodies in lymphoproliferative disease and of anti HER2 agents in breast tumors overexpressing the targeted antigens.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP491842.RAdAh8GIypCWaMVDqd9YuP8E2IHTGpgo6NLvfYwRw7kc0130_provenance.
• NP491838.RANTabECIqPP5e-g7pu1CnmyJnveRE94ygaRHXlwTr2Aw130_assertion description "[This assumption has been derived by the successful development of BCR/ABL tyrosine kinase inhibitors in human chronic myeloid leukemia as well as on the activity of antiCD20 monoclonal antibodies in lymphoproliferative disease and of anti HER2 agents in breast tumors overexpressing the targeted antigens.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP491838.RANTabECIqPP5e-g7pu1CnmyJnveRE94ygaRHXlwTr2Aw130_provenance.
• NP379040.RAk0C0BGaE4FpilLi7Ur02uHJLrq5Kt8CZ9K1DKS-dYJA130_assertion description "[This assumption has been derived by the successful development of BCR/ABL tyrosine kinase inhibitors in human chronic myeloid leukemia as well as on the activity of antiCD20 monoclonal antibodies in lymphoproliferative disease and of anti HER2 agents in breast tumors overexpressing the targeted antigens.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP379040.RAk0C0BGaE4FpilLi7Ur02uHJLrq5Kt8CZ9K1DKS-dYJA130_provenance.
• NP491837.RAsnXdIdIPVZJ5VlaY3oyEiN86Hsp85WCrQF12orcD8L4130_assertion description "[This assumption has been derived by the successful development of BCR/ABL tyrosine kinase inhibitors in human chronic myeloid leukemia as well as on the activity of antiCD20 monoclonal antibodies in lymphoproliferative disease and of anti HER2 agents in breast tumors overexpressing the targeted antigens.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP491837.RAsnXdIdIPVZJ5VlaY3oyEiN86Hsp85WCrQF12orcD8L4130_provenance.
• NP491839.RAj7JCVJBq3NqUHPsSnB9EWU-XMGlHdfjAgYe00Z7WB74130_assertion description "[This assumption has been derived by the successful development of BCR/ABL tyrosine kinase inhibitors in human chronic myeloid leukemia as well as on the activity of antiCD20 monoclonal antibodies in lymphoproliferative disease and of anti HER2 agents in breast tumors overexpressing the targeted antigens.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP491839.RAj7JCVJBq3NqUHPsSnB9EWU-XMGlHdfjAgYe00Z7WB74130_provenance.
• NP491840.RAltGD_oAWqhvKTySMKIesXlpK1rVWVc83zF0FWhHyb8k130_assertion description "[This assumption has been derived by the successful development of BCR/ABL tyrosine kinase inhibitors in human chronic myeloid leukemia as well as on the activity of antiCD20 monoclonal antibodies in lymphoproliferative disease and of anti HER2 agents in breast tumors overexpressing the targeted antigens.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP491840.RAltGD_oAWqhvKTySMKIesXlpK1rVWVc83zF0FWhHyb8k130_provenance.